Combining Incretin-Based Therapies With Insulin: Realizing the potential in type 2 diabetes

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

(2012) Matteo Monami et al.   ADVANCES IN THERAPY

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

(2012) Vanita R. Aroda et al.   CLINICAL THERAPEUTICS

Comment on: Greenbaum et al. Through the Fog: Recent Clinical Trials to Preserve  -Cell Function in Type 1 Diabetes. Diabetes 2012;61:1323-1330

(2012) B. Vialettes et al.   DIABETES

Response to Comment on: Marquez et al. Low-Frequency Variants in HMGA1 Are Not Associated With Type 2 Diabetes Risk. Diabetes 2012;61:524-530

(2012) P. Froguel et al.   DIABETES

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study

(2012) E. S. Hong et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study

(2012) B. Eliasson et al.   DIABETOLOGIA

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*

(2011) K. Y. Thong et al.   DIABETES OBESITY & METABOLISM

The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin Requirements

(2011) Wendy Lane et al.   Diabetes Technology & Therapeutics

Clinical Outcomes Using Long-Term Combination Therapy with Insulin Glargine and Exenatide in Patients with Type 2 Diabetes Mellitus

(2011) Philip Levin et al.   Endocrine Practice

Emergency Hospitalizations for Adverse Drug Events in Older Americans

(2011) Daniel S. Budnitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

(2011) Daisuke Yabe et al.   Journal of Diabetes Investigation

Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function

(2010) Sunder Mudaliar et al.   AMERICAN JOURNAL OF MEDICINE

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial

(2010) P. Hollander et al.   DIABETES OBESITY & METABOLISM

Time for Testing Incretin Therapies in Early Type 1 Diabetes?

(2010) Emanuele Bosi   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Exenatide therapy in insulin-treated type 2 diabetes and obesity

(2010) U. A. Nayak et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Exenatide added to insulin therapy: A retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

(2009) Nancy M. Yoon et al.   CLINICAL THERAPEUTICS

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus

(2008) V. Fonseca et al.   HORMONE AND METABOLIC RESEARCH

Enhanced Protection against Cytokine- and Fatty Acid-induced Apoptosis in Pancreatic Beta Cells by Combined Treatment with Glucagon-like Peptide-1 Receptor Agonists and Insulin Analogues

(2008) D. Tews et al.   HORMONE AND METABOLIC RESEARCH

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET